<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03273595</url>
  </required_header>
  <id_info>
    <org_study_id>KY20162048-1</org_study_id>
    <nct_id>NCT03273595</nct_id>
  </id_info>
  <brief_title>Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer</brief_title>
  <official_title>A Prospective, Open-label，Multicentre，Real-word Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as Neoadjuvant Therapy for Women With HER2-positive and p95HER2-positive，PI3K Mutation，or PTEN Loss Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, real-word study evaluating the efficacy and safety of&#xD;
      lapatinib in combination with chemotherapy versus trastuzumab in combination with&#xD;
      chemotherapy in women with HER2-positive and p95HER2-positive ,or PI3K mutation, or PTEN loss&#xD;
      breast cancer . Eligible subjects will have newly diagnosed breast cancer (Stage II-III) ;&#xD;
      not have received systemic or local treatment . The primary endpoint was the rate of&#xD;
      pathological complete response (pCR). The secondary objectives are to evaluate overall&#xD;
      survival, overall response rate, clinical benefit response rate and the safety as well as&#xD;
      tolerability of lapatinib plus chemotherapy and trastuzumab plus chemotherapy.&#xD;
&#xD;
      Patients will receive lapatinib 1000 mg daily or trastuzumab 4 mg/kg intravenous (IV) load&#xD;
      followed by 2 mg/kg IV weekly for a total of 12 weeks. After surgery, patients planned total&#xD;
      duration of the anti-HER2 therapy will be one year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response (pCR)</measure>
    <time_frame>at the end of week 12</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neoplasms, Breast</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female gender;&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer:&#xD;
&#xD;
          -  Primary tumour greater than 2 cm diameter, measured by clinical examination and&#xD;
             mammography or echography,&#xD;
&#xD;
          -  p95HER2 positive,or PI3K mutation,or PTEN loss&#xD;
&#xD;
          -  Over expression and/or amplification of HER2 in the invasive component of the primary&#xD;
             tumour [Wolff et al 2006] and confirmed by a certified laboratory prior to&#xD;
             randomisation&#xD;
&#xD;
          -  Known hormone receptor status.&#xD;
&#xD;
          -  Haematopoietic status:&#xD;
&#xD;
          -  Cardiovascular:&#xD;
&#xD;
          -  Baseline left ventricular ejection fraction (LVEF) ³ 50% measured by echocardiography&#xD;
             (ECHO) or Multiple Gate Acquisition (MUGA) scan,&#xD;
&#xD;
          -  Negative serum pregnancy test, within 2-weeks (preferably 7 days) prior to&#xD;
             randomization (For women of childbearing potential)&#xD;
&#xD;
          -  Fertile patients must use effective contraception (barrier method - condoms, diaphragm&#xD;
             - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable,&#xD;
             or implant hormonal contraceptives are not allowed)&#xD;
&#xD;
          -  Signed informed consent form (ICF)&#xD;
&#xD;
          -  Patient accepts to make available tumour samples for submission to central laboratory&#xD;
             to conduct translational studies as part of this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received any prior treatment for primary invasive breast cancer;&#xD;
&#xD;
          -  Previous (less than 10 years) or current history of malignant neoplasms, except for&#xD;
             curatively treated:&#xD;
&#xD;
          -  Basal and squamous cell carcinoma of the skin;&#xD;
&#xD;
          -  Carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Patients with a prior malignancy diagnosed more than 10 years prior to randomisation&#xD;
             may enter the study. Patients must have been curatively treated with surgery alone.&#xD;
             Radiation therapy or systemic therapy (chemotherapy or endocrine) are NOT permitted.&#xD;
             Prior diagnoses of breast cancer or melanoma are excluded.&#xD;
&#xD;
          -  Diagnosis of inflammatory breast cancer;&#xD;
&#xD;
          -  Bilateral cancer;&#xD;
&#xD;
          -  This criterion has been deleted from the protocol Version 1. Patients with multi-focal&#xD;
             cancer are no longer excluded.&#xD;
&#xD;
          -  Known history of uncontrolled or symptomatic angina, clinically significant&#xD;
             arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled&#xD;
             hypertension (≥180/110), unstable diabetes mellitus, dyspnoea at rest, or chronic&#xD;
             therapy with oxygen;&#xD;
&#xD;
          -  Concurrent disease or condition that would make the subject inappropriate for study&#xD;
             participation or any serious medical disorder that would interfere with the subject's&#xD;
             safety;&#xD;
&#xD;
          -  Unresolved or unstable, serious adverse events from prior administration of another&#xD;
             investigational drug;&#xD;
&#xD;
          -  Active or uncontrolled infection;&#xD;
&#xD;
          -  Dementia, altered mental status, or any psychiatric condition that would prevent the&#xD;
             understanding or rendering of ICF;&#xD;
&#xD;
          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or&#xD;
             resection of the stomach or small bowel. Subjects with ulcerative colitis are also&#xD;
             excluded;&#xD;
&#xD;
          -  Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy,&#xD;
             biologic therapy other than the trial therapies);&#xD;
&#xD;
          -  Concurrent treatment with an investigational agent or participation in another&#xD;
             therapeutic clinical trial;&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to trastuzumab or lapatinib or their excipients;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Concomitant use of CYP3A4 inhibitors or inducers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Ling, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rui Ling, Doctor</last_name>
    <phone>+862984775271</phone>
    <email>lingrui0105@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juliang Zhang, Doctor</last_name>
    <phone>+862984775271</phone>
    <email>zhangjl@fmmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliang Zhang, Doctor</last_name>
      <phone>+862984775271</phone>
      <email>zhangjl@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Juliang Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

